Milestone Pharmaceuticals Inc (MIST)

$MIST 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States.

Exchange

NASDAQ

Website

www.milestonepharma.com

$15M

Total Revenue

28

Employees

$231M

Market Capitalization

-7.52

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 21578 2286 2.88 20.15 13.26
Organon & Co. OGN 7323 7878 -4.52 4.82 19.26
Arvinas Inc ARVN 3963 23 4.93 -19.95 -794.96
Tilray Inc TLRY 2976 564 0.99 -7.48 -66.49
Usana Health Sciences Inc USNA 2079 1230 4.83 15.14 11.04
ATAI Life Sciences N.V. ATAI 1782 20 3.94 -10.71 -821.63
Cronos Group Inc CRON 1527 57 0.96 -10.58 -258.59
DICE Therapeutics Inc DICE 1211 1 3.72 -30.64 None
NRX Pharmaceuticals Inc NRXP 1170 2321 0.45 5.05 9.91
Intersect ENT Inc XENT 894 104 56.42 -10.10 -85.02
Ventyx Biosciences Inc VTYX 877 -10.72 -10.48 None
Phibro Animal Health Corp. PAHC 825 853 3.49 16.77 5.70
Edgewise Therapeutics Inc EWTX 793 2.79 -21.86 None
Phathom Pharmaceuticals Inc PHAT 673 5.72 -4.13 None
Theseus Pharmaceuticals Inc THRX 567 -12.12 -26.25 None
Cyteir Therapeutics Inc CYT 548 2.80 -15.36 None
Rani Therapeutics Holdings Inc RANI 514 3 9.84 -25.43 -678.00
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Pliant Therapeutics Inc PLRX 475 10 2.16 -5.04 -914.12
Fulcrum Therapeutics Inc FULC 472 18 2.59 -6.30 -409.62
Ikena Oncology Inc IKNA 465 11 2.28 -7.38 -581.21
Provention Bio Inc PRVB 399 1 3.08 -3.27 None
Rain Therapeutics Inc RAIN 350 413 2.42 -9.15 123.20
Chromadex Corp CDXC 299 65 8.71 -10.53 -42.83
Adicet Bio Inc ACET 279 10 1.52 4.84 -570.14
Verrica Pharmaceuticals Inc VRCA 241 12 6.26 -6.30 -320.98
Evolus Inc EOLS 239 86 3.10 -1.40 -162.78
Milestone Pharmaceuticals Inc MIST 231 15 1.32 -7.52 -230.90
Aquestive Therapeutics Inc AQST 194 47 -3.59 -3.11 -132.11
Terns Pharmaceuticals Inc TERN 193 1.13 -5.54 None
Cognition Therapeutics Inc CGTX 185 -2.24 -15.75 None
Anebulo Pharmaceuticals Inc ANEB 149 7.62 -3.81 None
Citius Pharmaceuticals Inc CTXR 134 1.68 -5.85 None
Opiant Pharmaceuticals Inc OPNT 134 44 3.01 107.00 3.58
Kaleido Biosciences Inc KLDO 132 1 4.80 -1.48 None
Xeris Biopharma Holdings Inc XERS 124 35 -100.00 -1.36 -265.78
scPharmaceuticals Inc SCPH 115 119 1.85 -4.10 -27.05
Kala Pharmaceuticals Inc KALA 107 12 1.84 -0.85 None
LifeMD Inc LFMD 107 78 -6.93 -0.96 -95.77
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Eyenovia Inc EYEN 94 6 24.00 -4.74 -332.81
Eton Pharmaceuticals Inc ETON 92 16 5.75 -8.36 -67.52
Natural Alternatives Internati NAII 78 177 0.97 6.99 6.64
Osmotica Pharmaceuticals Plc OSMT 76 166 1.83 -0.75 -60.32
Mannatech Inc MTEX 70 159 2.68 9.09 5.00
Odonate Therapeutics Inc ODT 58 0.83 -0.57 None
India Globalization Capital In IGC 58 0 2.05 -5.00 -981.18
Context Therapeutics Inc CNTX 57 -2.81 -8.19 None
Assertio Holdings Inc ASRT 55 108 0.65 -1.32 -28.04
Shineco Inc SISI 55 3 2.23 -1.07 None
VYNE Therapeutics Inc VYNE 46 17 0.85 -0.83 -507.13
Shineco Inc TYHT 44 3 2.17 -1.55 -159.60
Reviva Pharmaceuticals Holding RVPH 39 1.52 -4.50 None
Acasti Pharma Inc ACST 29 0 0.47 -2.16 -611.47
Bio-Path Holdings Inc BPTH 25 0 1.02 -2.73 18.96
Nabriva Therapeutics Plc NBRV 23 20 0.63 -0.37 -266.57
Baudax Bio Inc BXRX 21 1 -1.35 -0.45 9.10
Cyanotech Corp. CYAN 21 35 1.15 10.12 6.09
Lexaria Bioscience Corp LEXX 20 1 2.76 -5.10 -445.15
Dermata Therapeutics Inc DRMA 20 0.45 -2.46 None
Trevi Therapeutics Inc TRVI 19 2.16 -0.54 None
Hoth Therapeutics Inc HOTH 16 1.45 -1.50 None
Timber Pharmaceuticals Inc TMBR 13 0 11.00 3.07 -527.55
Sonoma Pharmaceuticals Inc. SNOA 9 17 3.02 -1.72 -31.96

Here's What Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Shareholder Ownership Structure Looks Like

17d ago, source: Simply Wall St News

The big shareholder groups in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have power over the company. Generally speaking, ...

Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update

21d ago, source: PR Newswire

MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

22d ago, source: Yahoo Finance

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

Milestone Pharmaceuticals: Q3 Earnings Snapshot

21d ago, source: Houston Chronicle

Milestone Pharmaceuticals Inc. (MIST) on Friday reported a loss of $14.2 million in its third quarter. The Montreal-based company said it had a loss of 34 cents per share. The results surpassed Wall ...

Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

1d ago, source: YAHOO!Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) future prospects. Citius Pharmaceuticals, Inc., a specialty ...

Texthelp's Literacy Support Tool, Read&Write, Hits New Milestone of 35 Million Users

7h ago, source: Le Lézard

Texthelp, a global leader in literacy and accessibility technology, today announced that its literary support tool, Read&Write, is now used by 35 million people worldwide. Originally, Read&Write was ...

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

9d ago, source: Associated Press

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits ...

'A milestone victory': Jury holds pharmacies responsible for role in opioid crisis

9d ago, source: KCCI Des Moines

CVS, Walgreens and Walmart pharmacies recklessly distributed massive amounts of pain pills in two Ohio counties, a federal ...

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

10d ago, source: Benzinga.com

Upon closing, Arrowhead to receive $120 million upfront payment for Phase 1/2 program for NASH - Arrowhead eligible to receive potential milestone payments and royalties ...

Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study

4d ago, source: Business Insider

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced it has completed enrollment of its 1,000 patient Phase 3 RESUME-1 Study of ...

Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript

10d ago, source: The Motley Fool on MSN.com

Q4 2021 Earnings CallNov 22, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared ...

Milestone Pharmaceuticals: Q3 Earnings Snapshot

21d ago, source: SFGate

MONTREAL (AP) _ Milestone Pharmaceuticals Inc. (MIST) on Friday reported a loss of $14.2 million in its third quarter. The Montreal-based company said it had a loss of 34 cents per share.

Your Portfolio